Cumberland Pharmaceuticals Inc. (CPIX) Company Bio
Cumberland Pharmaceuticals Inc., a specialty pharmaceutical company, focuses on acquiring, developing, and commercializing branded prescription products for the hospital acute care and gastroenterology markets in the United States and internationally. The company was founded in 1999 and is based in Nashville, Tennessee.
CPIX Price Forecast Based on DCF Valuation
DCF Fair Value Target:
Below please find a table outlining a discounted cash flow forecast for CPIX, in which we model out valuation assuming a variety of terminal growth rates. To summarize, we found that Cumberland Pharmaceuticals Inc ranked in the 27th percentile in terms of potential gain offered. We should note, though, that all scenearios modelled for this stock suggest it is overvalued. The most interesting components of our discounted cash flow analysis for Cumberland Pharmaceuticals Inc ended up being:
The stock's equity weight, or the proportion of capital from equity relative to debt, is 72. Its equity weight surpasses that of only 23.83% of free cash flow generating stocks in the Healthcare sector.
Cumberland Pharmaceuticals Inc's interest coverage rate -- a measure of gross earnings relative to interest payments -- comes in at -12.15. This coverage rate is greater than that of merely 7.05% of stocks we're observing for the purpose of forecasting via discounted cash flows.
Terminal Growth Rate in Free Cash Flow
Return Relative to Current Share Price
ABC, EDAP, WST, ABT, and AZN can be thought of as valuation peers to CPIX, in the sense that they are in the Healthcare sector and have a similar price forecast based on DCF valuation.
The 800+ hedge funds and famous money managers tracked by Insider Monkey have already compiled and submitted their 13F filings for the third quarter, which unveil their equity positions as of September 30. We went through these filings, fixed typos and other more significant errors and identified the changes in hedge fund portfolios. Our extensive […]
NASHVILLE, Tenn., Nov. 10, 2020 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX), a specialty pharmaceutical company, today is providing a company update and third quarter 2020 financial results. Net revenues from continuing operations during the quarter were $9.3 million….
Cumberland (NASDAQ: CPIX) unveils its next round of earnings this Tuesday, November 10. Get prepared with Benzinga's ultimate preview for Cumberland's Q3 earnings.Net Income, Earnings, And Earnings Per Share Earnings and especially earnings per share (EPS) are useful measures of a company's profitability. Total earnings, which is also referred to as net income, equals total revenue minus total expenses. EPS equals to net income divided by the number of shares outstanding.Earnings And Revenue Analysts covering Cumberland have modeled for quarterly EPS loss of $0.07 on revenue of $8.61 million. In the same quarter last year, Cumberland reported EPS of $0.01 on revenue of $10.37 million.Why Analyst Estimates And Earnings Surprises Are Important Analysts who cover this company will publish ...
UPDATE AVAILABLE ON-DEMAND According to the research report published by Allied Market Research, the global Intravenous (IV) Ibuprofen market is expected to register a CAGR of 20.0% from 2016 to 2022. The research includes changing market dynamics, top impacting factors, key
NASHVILLE, Tenn., Aug. 18, 2020 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX), a specialty pharmaceutical company, today announced the results of a new review of clinical studies evaluating Caldolor® (ibuprofen) Injection, which was published in the journal Clinical…